Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trumenba Safety Study in Adolescents and Young Adults
NCT01352793Phase 3Completed
- Sponsor
- Pfizer
- Start
- Nov 2012
- Primary completion
- Sep 2014
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial of meningococcal group B vaccine in meningococcal meningitis (2 arms), sponsored by Pfizer. Primary endpoints: Percentage of Participants With at Least One Serious Adverse Event and Percentage of Participants With at Least One Medically Attended Adverse Event. Started Nov 2012; status: completed.
02
Drugs
meningococcal group B vaccine
03
Conditions
meningococcal meningitis
Beyond the preview
Go deeper on NCT01352793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01352793.